



Impairment of interferon regulatory factor-3 activation by hepatitis C virus core protein basic amino acid region 1

Kazuaki Inoue^{a,b}, Kyoko Tsukiyama-Kohara^{a,c,d}, Chiho Matsuda^a, Mitsutoshi Yoneyama^e, Takashi Fujita^f, Shusuke Kuge^g, Makoto Yoshiba^b, Michinori Kohara^{a,*}

^a Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan

^b Division of Gastroenterology, Showa University Fujigaoka Hospital, 1-30 Aoba-ku, Fujigaoka, Yokohama 227-8501, Japan

^c Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto City, Kumamoto 860-8556, Japan

^d Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima City, Kagoshima 890-0065, Japan

^e Medical Microbiology Research Center, Chiba University, 1-8-1 Inohana Chuo-Ku, Chiba-City, Chiba 260-8673, Japan

^f Laboratory of Molecular Genetics, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan

^g Laboratory of Microbiology, Tohoku Pharmaceutical University, Komatsushima, Aoba-ku, Sendai 981-8558, Japan

ARTICLE INFO

Article history:

Received 17 October 2012

Available online 30 October 2012

Keywords:

Hepatitis C virus

IRF-3

Core protein

Type I interferon signaling

Basic amino acid region 1

Interferon beta

ABSTRACT

Interferon regulatory factor-3 (IRF-3), a key transcriptional factor in the type I interferon system, is frequently impaired by hepatitis C virus (HCV), in order to establish persistent infection. However, the exact mechanism by which the virus establishes persistent infection has not been fully understood yet. The present study aimed to investigate the effects of various HCV proteins on IRF-3 activation, and elucidate the underlying mechanisms. To achieve this, full-length HCV and HCV subgenomic constructs corresponding to structural and each of the nonstructural proteins were transiently transfected into HepG2 cells. IFN- β induction, plaque formation, and IRF-3 dimerization were elicited by Newcastle disease virus (NDV) infection. The expressions of IRF-3 homodimer and its monomer, Ser386-phosphorylated IRF-3, and HCV core protein were detected by immunofluorescence and western blotting. IFN- β mRNA expression was quantified by real-time PCR (RT-PCR), and IRF-3 activity was measured by the levels of IRF-3 dimerization and phosphorylation, induced by NDV infection or polyriboinosinic:polyribocytidylic acid [poly(I:C)]. Switching of the expression of the complete HCV genome as well as the core proteins, E1, E2, and NS2, suppressed IFN- β mRNA levels and IRF-3 dimerization, induced by NDV infection. Our study revealed a crucial region of the HCV core protein, basic amino acid region 1 (BR1), to inhibit IRF-3 dimerization as well as its phosphorylation induced by NDV infection and poly (I:C), thus interfering with IRF-3 activation. Therefore, our study suggests that rescue of the IRF-3 pathway impairment may be an effective treatment for HCV infection.

© 2012 Elsevier Inc. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Hepatitis C virus (HCV), a flavivirus comprising a positive-sense, single-stranded RNA (ssRNA) of approximately 9.6 kb [1], causes persistent disease in infected individuals, possibly leading to chronic liver injury [2]. Despite the approximately 170 million individuals worldwide suffering from HCV infection that ranges from chronic hepatitis to hepatocellular carcinoma (HCC) [3,4], the exact mechanism by which the virus establishes persistent infection is not fully resolved.

The innate immune system is activated immediately upon infection as the first line of host defense against invading pathogens, with type I interferon (IFN) signaling being the crucial step

in the antiviral response [5]. The IFN system is, therefore, a prime target of HCV and other viruses in order to establish persistent infections [6], wherein the disruption of the type I IFN-activation pathway forms the most efficient strategy for HCV. Studies on HCV IFN-interference mechanisms have revealed that the HCV proteins NS5A and E2 selectively inhibit the double-stranded RNA-activated protein kinase (PKR) [7,8], an IFN-inducible antiviral molecule that controls transcription and translation [6]. IFN- β , a crucial molecule in type I IFN signaling, is regulated by several cellular factors associated with the activation of interferon regulatory factor-3 (IRF-3), leading to its rapid induction following viral infection [9,10]. However, IFN- β induction is impaired in HCV-infected cells, thus resulting in the disruption of IFN downstream signaling cascade [11].

IRF-3, a key constitutively expressed transcriptional factor localized in the cytoplasm in its inactive form [9], is activated upon

* Corresponding author. Fax: +81 3 5316 3137.

E-mail address: kohara-mc@igakuken.or.jp (M. Kohara).

phosphorylation, whereby it translocates to the nucleus to act as a transcriptional factor for positive regulatory domain (PRD) 1 of the IFN- β promoter. IRF-3 activation also induces phosphorylation of Ser385 and Ser386 or the serine/threonine (Ser/Thr) cluster between amino acids (aa) 396 and 405 (located at the C-terminus of IRF-3), a step that is essential for dimerization and nuclear translocation.

A previous study by Foy et al. showed that the NS3/4A serine protease derived from a subgenomic replicon participates in the suppression of the cellular pathway that activates IRF-3 [12]. The NS3/4A protein of HCV disrupts signaling of the double-stranded RNA (dsRNA) receptors, retinoic acid-inducible gene-I (RIG-I), and Toll-like receptor 3 (TLR3) by inducing proteolysis of interferon promoter stimulator-1 (IPS-1) [13–15] and Toll/interleukin-1 receptor (TIR) domain-containing adaptor protein inducing IFN- β (TRIF) [16], as well as by suppressing the downstream activation of IFN- β [13].

In view of the above observations and the emerging data on the role of HCV in regulating the IRF-3 pathway by additional

mechanisms, we aimed to investigate the effects of various HCV proteins on IRF-3 activation, and further elucidate the underlying novel mechanisms.

2. Material and methods

2.1. Transient expression of the HCV core proteins E1, E2, and NS3–4A

HepG2 cells were transfected to express E1, E2, or NS3–4A HCV core protein under the control of EF promoter (Invitrogen). The HCV core expression vectors were derived from HCR6 (genotype 1b), HCR24–12K (genotype 2a), or HCR24–12Q (genotype 2a). The E1, E2, and NS3 clones derived from HCR6 contained either the full-length cDNAs encoding the core protein or 1 of the 3 different deletions (deletion mutants), each of which lacked 1 of the 3 basic amino acid regions (BR), BR1 deletion (aa 4–14), BR2 deletion (aa 37–44), and BR3 deletion (aa 57–72) [17]. HepG2 cells were transfected with 4 μ g of the core cDNA (amino acids 1–191), E1 (amino




Fig. 1. (A) Structures of the conditional expression vectors for HCV RNAs and proteins. The cDNA clones that displayed highest level of homology to the consensus sequences among the 3 clones were used to construct HCR6-Rz (nt 1–9611). HCR6-Fse clone harbored a termination codon introduced at nucleotide 3606 and truncated HCR6-Age clone lacked nucleotides 155–1967. They were flanked with ribozyme (Rz) and hepatitis D virus ribozyme (HDV-Rz) sequences under the control of the CAG promoter in the Cre/loxP switching expression cassette, which consisted of the neomycin resistance gene, as a stuffer region flanked by the loxP sequence. (B) IFN- β mRNA levels in the cell lines HCR6-Rz, HCR6-Fse, and HCR6-Age before and after the expression of the HCV protein. The results are expressed as copy numbers per microgram of total RNA, as quantified by RT-PCR. (C) Efficiency of NDV plaque formation. Plaque assays were performed on Vero cells for NDV infectivity in HCR6-Rz, HCR6-Fse, or HCR6-Age before and after the expression of the HCV genome. The plaque numbers were counted 3 days after NDV inoculation. The ratio indicates the plaque numbers after the expression of the HCV genome divided by the plaque numbers before the expression of the HCV genome. Day 0, before the expression of the HCV genome; Day 48, after the expression of the HCV genome. The results are expressed relative to the levels on Day 0 (100%) in each of the 3 HCV-expressing systems. p.i.h., post-inoculation hour. (D) Suppression of IFN- β mRNA induction by HCV expression, 18 days after NDV inoculation. Day 0, before the expression of the HCV genome; Day 48, after the expression of the HCV genome. The results are expressed relative to the levels on Day 0 (100%) in each of the 3 HCV-expressing systems. p.i.h., post-inoculation hour.

acids 192–383), E2 (amino acids 384–809), NS3-4A (amino acids 1027–1711), or the core regions lacking the BR, in 35-mm dishes, by using Lipofectamine 2000 (Invitrogen) at 37 °C for 6 h. The medium was subsequently replaced with normal culture medium, and the cells were harvested after 48 h.

2.2. Newcastle disease virus (NDV) infection and addition of polyriboinosinic:polyribocytidylic acid [poly(I:C)]

NDV (Miyadera strain) was propagated from swabs by using the embryonated egg culture method, as described in the Supplementary methods.

Poly(I:C) (20 µg/well; GE Healthcare) was added to HepG2 cells in 35-mm dishes, 48 h after transfection with the core expression vector derived from HCR6 (genotype 1b).

2.3. Native PAGE of IRF-3 and phosphorylated IRF-3

Cells were lysed in 30 µL of lysis buffer (50 mM Tris–HCl [pH 8.0], 1% NP-40, 150 mM NaCl, 100 µg/mL leupeptin, 1 mM PMSF, 5 mM Na₃VO₄), mixed vigorously, and centrifuged at 15,000 rpm for 10 min; the supernatant was isolated. Total protein samples (10 µg) were electrophoresed on a 7.5% native PAGE gel (Bio-Rad Laboratories) and transferred onto a PVDF membrane. IRF-3 homodimer and its monomer and Ser386-phosphorylated IRF-3 were detected by western blotting using polyclonal rabbit antibodies, anti-human IRF-3 (1:1000) [18] and, anti-human Ser386-phosphorylated IRF-3 (1:10,000), respectively. Detection was achieved by enhanced chemiluminescence (ECL; Amersham, UK) according to the manufacturer's instructions. The rabbit anti-human IRF-3 and anti-human Ser386-phosphorylated IRF-3 antibodies were described previously [19].

2.4. Quantification of IFN-β gene expression

IFN-β mRNA expression was quantified by using real-time PCR (RT-PCR) as described previously [20] and Supplementary methods using the following primers and probes: sense (5'-CCATCTATGA GATGCTCCAGAA-3'), antisense (5'-TTTCTCTCCAGGACTGTCTCA-GA-3') and probe (5'-AGCACTGGCTGGAATGAGACTATTGTTG-3').

3. Results

3.1. Induction of IFN and IRF-3 by HCV-Rz

To evaluate the effect of HCV gene persistent expression, cell lines expressing the HCV genomes in a Cre/loxP expression system [20] were established by transfecting the full-genome HCV (HCR6-Rz); core, E1, E2, and NS2 (HCR6-Fse); and E2~NS5b (HCR6-Age) (Fig. 1A) clones into HepG2 cells. Of the 3 HCV expression systems, only HCR6-Rz transiently induced endogenous IFN-β expression (Fig. 1B). No endogenous IFN-β was detected by RT-PCR on Day 0 or Day 48 (long culture; LC) [21] in any of the 3 systems (Fig. 1B).

3.2. Effect of HCV expression on NDV infection and IFN-β induction

Further, we examined whether the persistent expression of HCV genome influenced the plaque formation activity of NDV in HCR6-Rz-, HCR6-Fse-, and HCR6-Age-expressing cell lines. Prior to the expression of HCV proteins, the plaque numbers were similar across all the cell lines (Fig. 1C). Expression of HCV proteins for more than 48 days [21] increased plaque numbers in the HCR6-Rz- and HCR6-Fse-expressing cells from 7- to 8-fold (Fig. 1C); however, plaque numbers in the HCR6-Age-expressing cells remained constant. These findings thus indicate that HCV structural proteins

interfered with the induction of IFN-β mRNA, after NDV infection (18 h post-infection). Therefore, we measured IFN-β mRNA levels in the 3 cell lines, HCR6-Rz, HCR6-Fse, and HCR6-Age, by RT-PCR before (Day 0) and after (Day 48) inoculation with NDV (Fig. 1D). The mRNA expression of IFN-β was not observed prior to NDV infection in any of the 3 cell lines (Day 0). Notably, after 18 h of NDV inoculation and prior to the expression of various HCV proteins (Day 0), the levels of IFN-β mRNA transcription were similar among HCR6-Rz-, HCR6-Fse-, and HCR6-Age-expressing cell lines (Fig. 1D). Following HCV protein expression, the induced IFN-β mRNA expression was reduced to 20% in both HCR6-Rz- and HCR6-Fse-expressing cell lines. However, IFN-β mRNA expression remained constant in the HCR6-Age-expressing cell line.




Fig. 2. (A) HCV inhibition of IRF-3 nuclear translocation. IRF-3 is a constitutively expressed transcriptional factor that localizes in the cytoplasm in a diffuse manner, when inactive. After NDV inoculation and prior to the expression of the HCV genome, IRF-3 translocated to the nucleus but was retained at a perinuclear site in the HCR6-Rz-expressing cells (Day 48). IRF-3 colocalized with the HCV core protein. (B–D) Suppression of IRF-3 dimerization by HCV expression. The dimeric and monomeric forms of IRF-3 were detected by western blotting on native PAGE gels. The influence of (B) HCR6-Rz expression, (C) HCR6-Fse expression, and (D) HCR6-Age expression on IRF-3 dimerization is shown. NDV was used to induce IRF-3 dimerization.




Fig. 3. (A) Structures of the HCR6 core, E1, and E2 expression vectors encoding the HCV core (aa 1–191), E1 (amino acids 192–383), and E2 (amino acids 384–809) proteins, respectively, under the control of the EF1 promoter. (B) Left panel, IRF-3 dimerization induced by NDV before transfection with the expression vectors; right panel, IRF-3 dimerization induced by NDV after transfection with the expression vectors. (C) IFN- β mRNA induction levels at 12 and 18 h after NDV inoculation into HepG2 cells transfected with the vector alone, core, E1, or E2 proteins. The results are expressed relative to the induction levels of IFN- β in HepG2 cells transfected with the vector alone (100%), for post-inoculation, each time. (D) IRF-3 dimerization on administration of 10 mg/mL poly(I:C) before the expression (Day 0), and at 2, 4, 8, and 12 h after the expression of the HCV core (pEF1-Core) or vector plasmid DNA. (E) Effects of the expression of vector (lane 1), R6 core (lane 2), R24 core (lane 3), R24 core (Q12K) (lane 4), R6-NS3-4A (lane 5), N1-NS3-4A (lane 6), and mock control (lane 7) on IRF-3 dimerization (upper column a) and phosphorylation of serine residue at amino acid 386 in IRF-3 (lower column b), after infection with NDV for 18 h. (F) Effects of the expressions of R6-C, R24-C, R24-C(Q12K), and R6-NS3 on IFN- β induction, 18 h after NDV inoculation. The IFN- β mRNA levels were assayed by RT-PCR. The results are expressed relative to the induction levels of IFN- β in HepG2 cells transfected with the vector alone (100%).

3.3. Effect of HCV on IRF-3 localization, nuclear translocation, and dimerization by NDV

The effect of HCV expression on cellular localization of IRF-3 was analyzed in HCR6-Rz-expressing cells infected with NDV

before (Day 0) and after LC (Fig. 2A). Prior to NDV infection, IRF-3 was detected in the cytoplasm by immunofluorescence. Notably, after 18 h of NDV inoculation and prior to HCR6-Rz protein expression, when IFN- β induction and IRF-3 dimerization were maximal, a substantial amount of IRF-3 translocated to the nucleus.

However, this nuclear translocation was suppressed in the presence of HCV proteins (Fig. 2A) and resulted in the co-localization of the HCV core protein with IRF-3 at perinuclear sites (Fig. 2A, superimposed image of IRF-3 and core protein immunostaining).

To elucidate the mechanism underlying the suppression of IFN- β mRNA in HCR6-Rz- and HCR6-Fse-expressing cells, we examined the effect of HCV expression on IRF-3 dimerization after NDV infection (Fig. 2B). Interestingly, the levels of IRF-3 dimerization peaked at 12–18 h after NDV infection in the 3 cell lines lacking HCV expression (Day 0; Fig. 2). However, in the HCR6-Rz- and HCR6-Fse-expressing cell lines, IRF-3 dimerization was found to be significantly reduced, (Fig. 2B and C) when compared to that in the HCR6-Age-expressing cells (Fig. 2D).

3.4. Identification of the HCV genome region responsible for the inhibition of IRF-3 dimerization and IFN- β induction

To identify the HCV genome region responsible for suppression of IRF-3 dimerization, HepG2 cells were transfected to express the HCV core regions derived from HCR6, E1, or E2 (genotype 1b; Fig. 3A). Protein expression was confirmed by western blotting (data not shown). The HCV core protein suppressed IRF-3 dimerization, but E1 and E2 expressions had no effect on the dimerization (Fig. 3B). Expression of E1, E2, or the vector alone did not alter the levels of IFN- β mRNA induced by NDV infection in HepG2 cells (Fig. 3C), but significantly reduced IFN- β mRNA levels at both 12 and 18 h after infection (Fig. 3C).

3.5. Effect of HCV core protein expression on IRF-3 dimerization through TLR3

Among the synthetic dsRNAs, poly(I:C) is a potent inducer of IFN- β through TLR3. Accordingly, HepG2 cells transfected with poly(I:C) and the vector control (pEF1-vector) showed IRF-3 dimerization (Fig. 3D). In contrast, IRF-3 dimerization was suppressed in HepG2 cells expressing the HCV core protein albeit the induction of IFN- β mRNA following poly(I:C) expression (data not shown).

3.6. Effect of the HCV core protein NS3 and core proteins derived from genotype 2a on IRF-3 dimerization, compared to proteins derived from genotype 1b

Further, we investigated whether the HCV core protein NS3 and core proteins derived from other genotypes exerted the same effects on IRF-3 after 18 h of NDV infection. The core proteins derived from genotypes 1b (R6) and 2a (R24-12Q and R24-12K) suppressed IRF-3 dimerization in cells infected with NDV (Fig. 3E(a)). In contrast, IRF-3 dimerization remained unaltered in the presence of R6 clone NS3 protein, but was suppressed by the N clone NS3 protein. Thus, NS3-4A protein of R6 clone suppressed IRF-3 dimerization to a relatively lesser extent compared to that of the N1 strain. Similar results were obtained for the phosphorylation at Ser386 in IRF-3 (Fig. 3E(b)). The IFN- β mRNA transcription was quantified in HepG2 cells by RT-PCR after transfection with these expression vectors (Fig. 3F).

3.7. Identification of the HCV core region responsible for suppressing IRF-3 dimerization

We sought to identify the region of the HCV core protein responsible for suppressing IRF-3 dimerization. Expression vectors encoding the entire HCV core or the core region lacking 1 of the 3 basic amino acid regions (BR) that influenced nuclear translocation [17] were transfected into HepG2 cells, and the effects on IRF-3 dimerization were examined (Fig. 4A). Protein




Fig. 4. (A) Structures of the HCR6 core, E1, and E2 expression vectors carrying the complete core, BR1 deletion (aa 4–14), BR2 deletion (aa 37–44), and BR3 deletion (aa 57–72). (B) Western blotting to confirmed the expression of the mutated core proteins. (C) Effects of the expression of various mutated core proteins on IRF-3 dimerization and IRF-3 phosphorylation at Ser386, 18 h after NDV inoculation. (D) Effects of the expression of each type of core protein region on IFN- β mRNA synthesis, 18 h after NDV inoculation. The results are expressed relative to the induction levels of IFN- β in HepG2 cells transfected with the vector alone (100%). IFN- β mRNA levels were assayed by RT-PCR.

expression of the core and the deletion mutants (BR1, BR2, and BR3) was confirmed by western blotting (Fig. 4B). IRF-3 dimerization, phosphorylation at Ser386 of IRF-3, and induction of IFN- β mRNA were suppressed in HepG2 cells expressing the entire core, a deletion of BR2, or a deletion of BR3 (Fig. 4C), but not in cells expressing the BR1-deleted HCV core regions (Fig. 4C and D).

4. Discussion

The present study indicates that the HCV core protein inhibits IRF-3 dimerization, IRF-3 phosphorylation at Ser386, and IFN- β induction. In addition, our study showed that the effect of the core protein derived from genotype 1b was similar to that of the core protein derived from genotype 2a, indicating that the inhibitory effect of the core protein might be effective in several genotypes of HCV. These findings are corroborated by a previous study by Foy et al. [12] who showed that HCV NS3/4 disrupts virus-associated-kinase-mediated IRF-3 activation, which further results in the suppression of IRF-3 phosphorylation, nuclear translocation, and IRF-3-dependent ISRE/PRDI activation. These findings indicate that attenuation of the IFN system was achieved through NS3/4A proteins via the interference of IRF-3 activation, thus strengthening our results, which show the potential of HCV core protein to interfere with IRF-3 activation in promoting persistent infection.

Furthermore, the present study showed that the N-terminal region of the core protein and BR-1 domain in particular are responsible for inactivating IRF-3. The N-terminal region (amino acids 1–59) of the HCV core protein has been identified as the binding region for a DEAD box protein (DDX3) [22]. Human DDX3, a putative RNA helicase, is a member of the highly conserved DEAD box subclass that includes the expression of murine PL10, *Xenopus* An3, and yeast Ded 1 proteins. Recently, expression of DDX3 was found to enhance IFN- β promoter induction by TBK1/IKK ϵ , whereas silencing of DDX3 inhibited IFN- β promoter and virus- or dsRNA-induced IRF-3 activation [23]. It was shown that Vaccinia virus K7 protein also binds to DDX3 and inhibits pattern recognition receptor-induced IFN- β induction by preventing TBK1/IKK ϵ -mediated IFN- β induction via impaired TBK1/IKK ϵ -induced activation of IRF-3 [23]. A previous study by Oshiumi et al. showed that DDX3 C-terminal region (amino acids 622–662) directly binds to the IFN-beta promoter stimulator-1 (IPS-1) CARD-like domain [24] as well as the N-terminal HCV core protein [36]. The present study demonstrated that the expression of the core protein decreased the levels of DDX3 expression (data not shown). This is in agreement with the result of a previous study, which showed that DDX3 is downregulated in HCV-associated hepatocellular carcinoma (HCC) and silencing of DDX3 accelerates cell growth [25]. Collectively, these findings suggest that DDX3 may be the target of the core protein for inhibiting IRF-3 activation.

In conclusion, our study revealed a crucial region of the HCV core protein, basic amino acid region 1, to interfere with IRF-3 activation and thereby inhibit the IFN signaling cascades. Therefore, the inhibitory effects that result in the IRF-3 pathway impairment could be rescued by deleting the basic region 1 of core protein, thus suggesting that it might be an effective treatment for HCV infection. Future studies involving DDX3 modification by the HCV core protein may be interesting to explore the cell growth-dysregulation mechanisms.

Acknowledgments

This study was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a grant from the Ministry of Health, Labour and Welfare of Japan; and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan; and the Cooperative Research Project on Clinical and

Epidemiological Studies of Emerging and Re-emerging Infectious Diseases.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bbrc.2012.10.079>.

References

- [1] N. Kato, M. Hijikata, Y. Ootsuyama, et al., Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis, *Proc. Natl. Acad. Sci. USA* 87 (1990) 9524–9528.
- [2] L.B. Seeff, F.B. Hollinger, H.J. Alter, et al., Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study, *Hepatology* 33 (2001) 455–463.
- [3] H.B. El-Serag, Hepatocellular carcinoma and hepatitis C in the United States, *Hepatology* 36 (2002) S74–S83.
- [4] D. Thomas, The hepatitis C viruses, in: C. Hagedorn, C. Rice (Eds.), *Hepatitis C Epidemiology*, Springer-Verlag, Berlin, 1999, pp. 25–42.
- [5] G.R. Foster, Interferons in host defense, *Semin. Liver Dis.* 17 (1997) 287–295.
- [6] R. Kaufman, Translation control of genome expression, in: N. Sonenberg, J. Hershey, M. Matthews (Eds.), *The double strand RNA-activated protein kinase PKR*, Cold Spring Harbor, New York, 2000, pp. 503–527.
- [7] M.J. Gale Jr., M.J. Korth, N.M. Tang, et al., Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein, *Virology* 230 (1997) 217–227.
- [8] D.R. Taylor, S.T. Shi, P.R. Romano, et al., Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein, *Science* 285 (1999) 107–110.
- [9] M. Yoneyama, W. Suhara, Y. Fukuhara, et al., Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300, *Embo. J.* 17 (1998) 1087–1095.
- [10] J. Hiscott, Triggering the innate antiviral response through IRF-3 activation, *J. Biol. Chem.* 282 (2007) 15325–15329.
- [11] E.F. Meurs, A. Breiman, The interferon inducing pathways and the hepatitis C virus, *World J. Gastroenterol.* 13 (2007) 2446–2454.
- [12] E. Foy, K. Li, C. Wang, et al., Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease, *Science* 300 (2003) 1145–1148.
- [13] E. Meylan, J. Curran, K. Hofmann, et al., Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus, *Nature* 437 (2005) 1167–1172.
- [14] X.D. Li, L. Sun, R.B. Seth, et al., Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity, *Proc. Natl. Acad. Sci. USA* 102 (2005) 17717–17722.
- [15] R. Lin, J. Lacoste, P. Nakhaei, et al., Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKEpsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage, *J. Virol.* 80 (2006) 6072–6083.
- [16] K. Li, E. Foy, J.C. Ferreón, et al., Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF, *Proc. Natl. Acad. Sci. USA* 102 (2005) 2992–2997.
- [17] R. Suzuki, Y. Matsuura, T. Suzuki, et al., Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted, *J. Gen. Virol.* 76 (Pt 1) (1995) 53–61.
- [18] W. Suhara, M. Yoneyama, I. Kitabayashi, et al., Direct involvement of CREB-binding protein/p300 in sequence-specific DNA binding of virus-activated interferon regulatory factor-3 holocomplex, *J. Biol. Chem.* 277 (2002) 22304–22313.
- [19] M. Mori, M. Yoneyama, T. Ito, et al., Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation, *J. Biol. Chem.* 279 (2004) 9698–9702.
- [20] K. Tsukiyama-Kohara, S. Tone, I. Maruyama, et al., Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells, *J. Biol. Chem.* 279 (2004) 14531–14541.
- [21] T. Nishimura, M. Kohara, K. Izumi, et al., Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase, *J. Biol. Chem.* 284 (2009) 36442–36452.
- [22] A.M. Owsianka, A.H. Patel, Hepatitis C virus core protein interacts with a human DEAD box protein DDX3, *Virology* 257 (1999) 330–340.
- [23] M. Schroder, M. Baran, A.G. Bowie, Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation, *EMBO J.* 27 (2008) 2147–2157.
- [24] H. Oshiumi, K. Sakai, M. Matsumoto, T. Seya, DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta-inducing potential, *Eur. J. Immunol.* 40 (4) (2010) 940–948.
- [25] P.C. Chang, C.W. Chi, G.Y. Chau, et al., DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control, *Oncogene* 25 (2006) 1991–2003.